Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Enlivex Therapeutics Ltd., an Israeli company, for the month of March 2022. The report discloses a specific corporate event regarding intellectual property rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is not a financial statement but a disclosure of a material event.
Material Changes
On March 8, 2022, the Company announced the issuance of Israeli Patent Number 255119. The patent is entitled "Therapeutic Pooled Blood Apoptotic Cell Preparations And Uses Thereof." This grant provides added intellectual property protection in Israel extending at least until 2037. The patent claims cover the use of pooled donor cells as source materials for the Company's product, Allocetra™.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the context of the patent issuance.
Key Facts for Investor Verification
- Confirmation of the validity and scope of Israeli Patent Number 255119.
- Verification of the patent expiration date (at least 2037) and its impact on the commercial exclusivity of Allocetra™ in Israel.
- Assessment of whether this patent strengthens the Company's competitive position against potential generic competitors in the Israeli market.